Literature DB >> 12804985

Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.

Alessandro Zaccagna1, Alberto Bertone, Paolo Puiatti, Franco Picciotto, Tatiana Sprujevnik, Renato Santucci, Francesco Paolo Rossini.   

Abstract

Here we report a case of Pyoderma gangrenosum (PG) associated with Crohn's disease successfully treated with infliximab. The efficacy of this drug in many inflammatory diseases has already been reported, but its use in PG has only been seen in very few cases. Our study confirms that this therapy is a valid alternative solution for treating PG, which is often unresponsive to conventional therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804985

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  6 in total

Review 1.  Extraintestinal complications of inflammatory bowel disease.

Authors:  Tim Orchard
Journal:  Curr Gastroenterol Rep       Date:  2003-12

2.  Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.

Authors:  K Vandevyvere; F P Luyten; P Verschueren; R Lories; S Segaert; R Westhovens
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

Review 3.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

4.  Adalimumab therapy for recalcitrant pyoderma gangrenosum.

Authors:  Margaret A Fonder; Deborah L Cummins; Benjamin D Ehst; Grant J Anhalt; Jon H Meyerle
Journal:  J Burns Wounds       Date:  2006-11-20

Review 5.  Extraintestinal Manifestations of Inflammatory Bowel Disease.

Authors:  Stephan R Vavricka; Alain Schoepfer; Michael Scharl; Peter L Lakatos; Alexander Navarini; Gerhard Rogler
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

6.  Extensive ulcerations due to pyoderma gangrenosum in a child with juvenile systemic lupus erythematosus and C1q deficiency.

Authors:  Abanomi Hind; Al-Ghamdi Abdulmonem; Sulaiman Al-Mayouf
Journal:  Ann Saudi Med       Date:  2008 Nov-Dec       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.